Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

ME Bahar, HJ Kim, DR Kim - Signal transduction and targeted therapy, 2023 - nature.com
Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

Regulation of cell cycle progression by growth factor-induced cell signaling

Z Wang - Cells, 2021 - mdpi.com
The cell cycle is the series of events that take place in a cell, which drives it to divide and
produce two new daughter cells. The typical cell cycle in eukaryotes is composed of the …

An overview on the role of dietary phenolics for the treatment of cancers

PG Anantharaju, PC Gowda, MG Vimalambike… - Nutrition journal, 2016 - Springer
Plant derived phenolic compounds have been shown to inhibit the initiation and progression
of cancers by modulating genes regulating key processes such as:(a) oncogenic …

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

MC Mendoza, EE Er, J Blenis - Trends in biochemical sciences, 2011 - cell.com
The Ras-extracellular signal-regulated kinase (Ras-ERK) and phosphatidylinositol 3-kinase-
mammalian target of rapamycin (PI3K-mTOR) signaling pathways are the chief mechanisms …

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

L Santarpia, SM Lippman… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: The MAPK pathway comprises several key signaling components and
phosphorylation events that play a role in tumorigenesis. These activated kinases transmit …

The mTOR signalling pathway in human cancer

H Pópulo, JM Lopes, P Soares - International journal of molecular …, 2012 - mdpi.com
The conserved serine/threonine kinase mTOR (the mammalian target of rapamycin), a
downstream effector of the PI3K/AKT pathway, forms two distinct multiprotein complexes …

Melanocytic nevi and melanoma: unraveling a complex relationship

WE Damsky, M Bosenberg - Oncogene, 2017 - nature.com
Approximately 33% of melanomas are derived directly from benign, melanocytic nevi.
Despite this, the vast majority of melanocytic nevi, which typically form as a result of BRAF …

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

J Villanueva, A Vultur, JT Lee, R Somasundaram… - Cancer cell, 2010 - cell.com
BRAF is an attractive target for melanoma drug development. However, resistance to BRAF
inhibitors is a significant clinical challenge. We describe a model of resistance to BRAF …

The dynamic control of signal transduction networks in cancer cells

W Kolch, M Halasz, M Granovskaya… - Nature Reviews …, 2015 - nature.com
Cancer is often considered a genetic disease. However, much of the enormous plasticity of
cancer cells to evolve different phenotypes, to adapt to challenging microenvironments and …

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

KHT Paraiso, Y Xiang, VW Rebecca, EV Abel, YA Chen… - Cancer research, 2011 - AACR
This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor
PLX4720. Immunohistochemical staining of a tissue array covering all stages of melanocytic …